Shots: The EC approval is based on P-III ATTR-ACT study assessing Vyndaqel (tafamidis meglumine, 20/80mg) vs PBO in patients with ATTR-CM that demonstrated a reduction in mortality and frequency of […]readmore
Tags : Transthyretin Amyloid Cardiomyopathy